We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

26 hedge funds and large institutions have $4.87M invested in Protalix BioTherapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,030% more call options, than puts

Call options by funds: $1.41M | Put options by funds: $125K

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

32% more capital invested

Capital invested by funds: $3.7M → $4.87M (+$1.17M)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.09% less ownership

Funds ownership: 7.13% → 7.04% (-0.09%)

4% less funds holding

Funds holding: 27 → 26 (-1)

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
4
Closed
4
Calls
$1.41M
Puts
$125K
Net Calls
+$1.29M
Net Calls Change
+$409K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$118K
2
Citadel Advisors
Citadel Advisors
Florida
+$72.1K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$55K
4
CIBC World Market
CIBC World Market
Ontario, Canada
+$39.5K
5
Jane Street
Jane Street
New York
+$15.1K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$244K
2
DC
Davenport & Co
Virginia
-$23K
3
ACA
Aptus Capital Advisors
Alabama
-$15K
4
UBS Group
UBS Group
Switzerland
-$12.1K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$5.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$3.31M – – –
MIH
2
Meitav Investment House
Israel
$319K +$165 +150 +0.1%
Renaissance Technologies
3
Renaissance Technologies
New York
$308K +$118K +107,403 +92%
BCM
4
Bridgeway Capital Management
Texas
$183K – – –
Citadel Advisors
5
Citadel Advisors
Florida
$170K +$72.1K +65,750 +112%
BlackRock
6
BlackRock
New York
$140K +$3.43K +3,130 +3%
Jane Street
7
Jane Street
New York
$126K +$15.1K +13,743 +18%
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$68K +$55K +50,100 New
CIBC World Market
9
CIBC World Market
Ontario, Canada
$49K +$39.5K +36,000 New
IWM
10
IHT Wealth Management
Illinois
$36.7K +$5.26K +4,800 +22%
CPA
11
Capital Performance Advisors
California
$35.6K – – –
Two Sigma Advisers
12
Two Sigma Advisers
New York
$28.2K -$5.16K -4,700 -19%
AS
13
Altshuler Shaham
Israel
$17.1K +$13.7K +12,478 New
SSWM
14
Smith Salley Wealth Management
North Carolina
$16.5K – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$13.9K -$247 -225 -2%
Morgan Stanley
16
Morgan Stanley
New York
$11.3K – – –
National Bank of Canada
17
National Bank of Canada
Quebec, Canada
$8.36K – – –
TWC
18
TD Waterhouse Canada
Ontario, Canada
$8.16K – – –
PVH
19
Psagot Value Holdings
Israel
$8K – – –
Federated Hermes
20
Federated Hermes
Pennsylvania
$7.89K – – –
Bank of America
21
Bank of America
North Carolina
$4.07K -$66 -60 -2%
Barclays
22
Barclays
United Kingdom
$2.74K – – –
TCWA
23
Ten Capital Wealth Advisors
Washington
$1.37K +$121 +110 +12%
Osaic Holdings
24
Osaic Holdings
Arizona
$685 +$548 +500 New
FDCDDQ
25
Federation des caisses Desjardins du Quebec
Quebec, Canada
$343 – – –
1
2

PLX Hedge Fund Activity: Q4 2022 in Review

26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2022, worth a combined $4.87M — up 32% from $3.7M a quarter earlier.

Fund positioning in PLX was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $118K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $244K sold.

  • 26 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2022, down from 27 in Q3 2022.
  • Funds reported $4.87M of Protalix BioTherapeutics stock for Q4 2022, up 32% quarter-over-quarter.
  • 4 funds opened new Protalix BioTherapeutics positions in Q4 2022 and 4 closed out, a net change of 0 holders.
  • The largest Protalix BioTherapeutics buyer in Q4 2022 was Renaissance Technologies, an estimated $118K added.
  • The largest Protalix BioTherapeutics seller in Q4 2022 was Susquehanna International Group, an estimated $244K sold.

Based on aggregated 13F filings for Q4 2022.